Connects all stakeholders in the specialty pharmacy ecosystem to deliver a delightful patient experience.
Why join us?
Founded in 2015, Phil is a San Francisco-based Series D health-tech startup, pioneering a software therapy deployment platform for Specialty Pharmaceuticals that treat complex health conditions. Our mission is to ensure consistent, reliable and affordable access to complex therapeutics for our patient community. Partnering with pharmaceutical manufacturers, Phil offers digital patient access services to improve health outcomes for patients by delivering affordable and timely access to high-cost Specialty therapeutics. We recently completed our Series D financing led by Warburg Pincus, with $122M in capital raised to date. Headquartered in San Francisco with operational hubs in Scottsdale AZ and Columbus, OH, the company currently employs over 120 individuals and expects to double its employee base in the coming year. For more information on Phil, visit https://phil.us/
Market: Unlike the more commonly-used generic drugs, Specialty pharmaceutical products treat complex health conditions and constitute about 50% of the $400B U.S. prescription medication spend. Despite the therapeutic potential of these products, patients and their care teams face substantial obstacles to therapy access, affordability, and adherence.
Our approach: While these challenges have been traditionally addressed through call-center based ‘hub’ services, the Phil team has developed a next-generation suite of software tools to streamline and simplify this complex, distributed workflow spanning patients, prescribers, pharmacies, insurers, and manufacturers. Often described as ‘Shopify for Pharma’, Phil offers a “channel-in-a-box” platform for pharmaceutical manufacturers.
Impact to customers: The Phil platform drives efficiencies that result in up to 6x higher adherence and consequent revenue and 33% improvements in patient affordability at 1/10th the cost of conventional call-center based approaches. Consequently, our customers, Pharma manufacturers are able to launch new products and attain profitability in less than half the usual lead time.
Growth: In 2021, at least 8 new FDA-approved products are contracted to launch on the Phil platform. The company is forecasted to grow 5x y/y in 2021. Specialty drugs are an annual spend of quarter trillion dollars a year. Access to these drugs are catastrophically broken despite pharma manufacturers investing billions in call-center based traditional solutions to fix these challenges. We are the first to market and by far the leader in solving this meaningful problem. Our year end revenue forecast should easily take us past 10-digit valuation estimates at current market multiples.
Engineering at Phil
We work on 2 weeks sprint cycle and once the features or projects are decided based on business priorities we assign an owner for each of the features/projects. Owner is responsible for working with the product, design, QA, and other engineers to deliver it
Building a complex workflow engine for processing prescriptions that handles complicated rules and sensitive PHI data
Working at Phil
We value strong sense of ownership, ability to work with the team members, and understand the
Close to bart
Work from Home
Social impact driven
Interested in this company?
Skip straight to final-round interviews by applying through Triplebyte.